1201 APR 25

1209 3/16/96 #3 1201 630

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: C.P. Dorn, et al.

Serial No.: 08/5

08/525,870

Case No.: 19189IA

Art Unit:

Filed:

September 8, 1995

For:

MORPHOLINE COMPOUNDS ARE

USEFUL AS TACHYKININ RECEPTOR

**ANTAGONISTS** 

Assistant Commissioner for Patents Washington, D.C. 20231

Examiner:

avent: 150

PATENT

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

## **CERTIFICATE OF MAILING**

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO:

ASSISTANT COMMISSIONER FOR PATENTS

WASHINGTON, D.C. 20231

ON THE DATE APPEARING BELOW:

\_ DATE: 23 April 1996

Serial No.: 08/525,870 Case No.: 19189IA

Page 2

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

This Information Disclosure Statement is being filed prior to the receipt by Applicants of an Official action on the merits in the instant application.

Copies of the references that are cited on the attached form PTO-1449 are enclosed herewith. Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By [] WW fu

Reg. No. 35,382

Attorney for Applicant

MERCK & CO., INC.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(908) 594-3904

Date: April 23, 1996